Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Viracor, Cleveland Clinic Sign License Deal for Kidney Transplant Rejection Biomarker Test

NEW YORK – Diagnostics company Eurofins Viracor said on Monday that it has signed a licensing agreement with the Cleveland Clinic for exclusive rights to a urine biomarker test for detecting rejection in kidney transplant patients.

The test, which was developed by Cleveland Clinic researcher Robert Fairchild and University of Alabama researchers Roslyn Mannon, identifies RNA molecules in urine that are highly accurate for the diagnosis of rejection and elevated risk of rejection in kidney transplant patients. The partners are aiming to give clinicians a way to diagnose clinical acute rejection without a biopsy and to distinguish clinical acute rejection from other non-rejection causes of kidney dysfunction after transplant.

Eurofins Viracor said it will work with Fairchild to validate the diagnostic assay for use in patient testing.

Further terms of the deal were not disclosed.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more